05 Jul 2023 --- Janssen Pharmaceutical Companies has achieved positive results from testing the novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis. The immune-mediated disease causes skin cell overproduction, causing painful and itchy plaques.
